Inhalable Drugs Let Patients Take a Breather from Needles
Earlier this month, a team of researchers led by the University of Colorado at Boulder announced that the inhalable measles vaccine they developed could lead to vaccines for other diseases.
diabetes
Making Diabetes Less Painful to Deal With
Diabetes patients don’t always engage in the self-care needed to control the disease.
Vivostat’s Technology Turns Blood Into Surgical Glue
Vivostat is a Danish company that uses the patient’s blood to create a personalized surgical glue (fibrin sealant) that can be used for surgical procedures and the treatment of diabetic ulcers.
OraMed Pharmaceuticals and Its Oral Insulin Pill
Oramed Pharmaceuticals in Jerusalem is developing a product that could potentially revolutionize the way diabetes is treated.
Echo Therapeutics Rated Strong Spec Buy by Life Tech Capital
The significant differences between Echo Therapeutics’ Symphony system and the competition is the needle-free transdermal biosensor, clinical trials in the hospital setting and biosensor life.
[OneMedForum] OrSense: Non-Invasive Blood Monitoring Solutions
Israel-based OrSense is attempting to increase patient compliance with a non-invasive continuous glucose monitor based on optical technology.
Echo Therapeutics: Positive Developments for Needle-Free Monitoring System
On 11/19/09, the Company announced positive results in a pilot clinical study which included Prelude skin preparation and the placement of 10 Symphony tCGM biosensors on subjects with Type 1 or Type 2 Diabetes.
Spherix Shares Rise on Promising Diabetes Drug Data
Shares in Spherix shot up by 77 percent after the biotechnology company announced preliminary Phase III results for its Type 2 diabetes drug candidate.
[Company Profile] Echo Therapeutics
Echo Therapeutics of Franklin, Mass., has developed the Symphony tCGM System, a needle-free, wireless system that allows patients to painlessly and accurately monitor their blood glucose levels around the clock.
Covidien Launches Nationwide Type 2 Diabetes Campaign
The Our Resolution movement is focused around the discovery that gastric bypass surgery resolves diabetes in approximately 77 percent of morbidly obese patients.